Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
By F. Couch, S. Hart, Priyanka Sharma, A. Toland, Xianshu Wang, P. Miron, J. Olson, A. Godwin, V. Pankratz, Curtis L. Olswold and 31 more. Journal of Clinical Oncology, 2015
608 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/21677301512581d18eec47ec1b061cffe314205b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- N. Tung
- P. Conte
- S. Im
- A. Armstrong
- Pankaj Kumar
- Wei Li
- Bing-he Xu
- C. Goessl
Citations in the corpus
- Inherited Mutations in Women with Ovarian Carcinoma (2016, neutral): “RESULTS Overall, the median (range) age at diagnosis was 60 (28-91) years in patients recruited from UW and 61 (23-87) years in patients recruited from the GOG trials.”
- An overview of triple-negative breast cancer (2016, background): “Although mutations in other predisposition genes are observed among patients with TNBC, better cancer risk estimates are needed before these mutations are used for clinical risk assessment in relatives [50].”
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (2019, background): “Germline BRCAm breast cancers tend to affect younger patients, those with a strong family history of breast cancer and Ashkenazi Jewish ancestry [1, 3].”